Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Regorafenib and Yttrium-90 Transarterial Radioembolization for the Treatment of Unresectable Hepatocellular Cancer

Trial Status: active

This phase II trial tests the safety and side effects of regorafenib in combination with yttrium-90 (Y-90) transarterial radioembolization (TARE) and how well the combination works in treating patients with hepatocellular cancer (HCC) that cannot be removed by surgery (unresectable). Regorafenib blocks certain proteins, which may help keep tumor cells from growing. It may also prevent the growth of new blood vessels that tumors need to grow. Regorafenib is a type of kinase inhibitor and a type of antiangiogenesis agent. Radioactive drugs, such as Y-90, may carry radiation directly to tumor cells and not harm normal cells. Radioembolization, a type of radiation therapy, uses tiny beads that hold the Y-90. The beads are injected into the hepatic artery (the main blood vessel that carries blood to the liver). The beads collect in the tumor and the Y 90 gives off radiation. This destroys the blood vessels that the tumor needs to grow and kills the tumor cells. The radioactivity emitted may also activate the immune system to find and attack other tumor cells in the body. Giving regorafenib in combination with Y-90 TARE may be safe, tolerable, and/or effective in treating patients with unresectable HCC.